Notice of AGM and Annual Report

RNS Number : 3361V

e-Therapeutics plc

15 April 2016

 

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Notice of Annual General Meeting and Annual Report

Oxford and Newcastle, UK, 15 April 2016 - e-Therapeutics plc's (AIM: ETX) annual report and accounts for the year ended 31 January 2016, which includes the notice convening the Company's 2016 Annual General Meeting (AGM), has been posted to shareholders today.

The annual report can be downloaded from the Company's website at www.etherapeutics.co.uk/investors/financial-reports/ 

The 2016 AGM will take place at 12:30pm on 25 May 2016 at the offices of Bond Dickinson LLP, 4 More London Riverside, London, SE1 2AU.

-Ends-

Contacts:

e-Therapeutics plc Malcolm Young, CEO Steve Medlicott, Finance Director	Tel: [phone] www.etherapeutics.co.uk
Numis Securities Limited Michael Meade / Freddie Barnfield (Corporate Finance) James Black (Corporate Broking)	Tel: [phone] www.numis.com
Instinctif Partners Melanie Toyne Sewell / Jayne Crook / Emma Barlow	Tel: [phone] Email: [e-mail]

About e-Therapeutics plc

e-Therapeutics (AIM: ETX) is a drug discovery and development company with a proprietary discovery platform based on advances in network pharmacology and chemical biology.

The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's discovery activity is in immuno-oncology, addressing drug resistance to targeted cancer therapies, and antivirals. The platform is yielding multiple, highly potent, selective and diverse molecules at much higher yields than is reported for conventional drug discovery. 

The Company has generated a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; ETS2400, in Hedgehog pathway inhibition; and ETS5200, novel broad-spectrum antivirals. 

e-Therapeutics has also advanced selected drug candidates into clinical trials. A Phase IIb study of a drug candidate for major depressive disorder, ETS6103 is complete, plus Phase I clinical trials in cancer for ETS2101.   

The Company is well funded to advance its programmes. It is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk 

 

END

 

 

NOAEAPLSFENKEEF